Antonia M. Davidson

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants

Samit R. Joshi, Mark Johnson, M. Lataillade, 2021, Antimicrobial Agents and Chemotherapy.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.

A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson’s Disease

D. Margolin, Antonia M. Davidson, K. Matthews, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects

D. Furst, E. Keystone, J. Kay, 2021, British journal of clinical pharmacology.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.